KBY Biotech Indexv0.0.34
Search
← Pipeline|HOV-IIT-732

HOV-IIT-732

Phase 3
By HOVON
Source: Trial-derived·Trials: 1
Modality
Multispecific
MOA
TNFi
Target
FcRn
Pathway
RAS/MAPK
Prostate Ca
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
~Feb 2022
→ ~May 2023
Phase 2
~Aug 2023
→ ~Nov 2024
Phase 3
Feb 2025
→ Feb 2029
Phase 3Current
NCT06169993
1,364 pts·Prostate Ca
2025-02→2029-02·Active
1,364 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-152.9y awayPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P3
Active
Catalysts
Ph3 Readout
2029-02-15 · 2.9y away
Prostate Ca
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06169993Phase 3Prostate CaActive1364PANSS
Competitors (10)
DrugCompanyPhaseTargetMOA
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
GelinaritideAbbViePreclinicalFcRnCFTRmod
AZN-7403AstraZenecaPhase 2/3FGFRTNFi
TAK-8262TakedaNDA/BLATauTNFi
TalalemzoparlimabGilead SciencesPhase 1FcRnTNFi
SovafutibatinibModernaApprovedFcRnSHP2i
RibozanubrutinibGenmabApprovedGPRC5DTNFi
ITC-879Intra-CellularApprovedFcRnTYK2i
JAZ-8729Jazz PharmaPhase 2/3FcRnCAR-T BCMA
369-789Hansoh PharmaPhase 3PI3KαTNFi